Currently, the NCCN guidelines’ recommendation of olaparib as maintenance therapy for patients with germline BRCA1/2 mutations following platinum-based chemotherapy has established it as a standard of care, leveraging precision medicine to improve outcomes by targeting genetic vulnerabilities in pancreatic cancer [48]. The gene discussed is BRCA1; the disease is pancreatic neoplasm.